AndroGel vs Jatenzo: Head-to-Head Efficacy for Testosterone Replacement

Why No Direct Head-to-Head Trial Exists

Comparing these two drugs requires cross-trial interpretation because no randomized controlled trial has tested AndroGel against Jatenzo in the same patient population. This gap is common in TRT. Most testosterone formulations were approved against placebo or against their own dose-ranging arms, not against competing delivery systems.

The Endocrine Society's 2018 clinical practice guideline on testosterone therapy for men with hypogonadism states: "We suggest offering testosterone therapy to men with symptomatic testosterone deficiency to induce and maintain secondary sex characteristics and to improve sexual function, sense of well-being, and bone mineral density" [1]. That guideline does not rank one formulation above another. It recommends choosing based on patient preference, pharmacokinetics, cost, and side-effect profile.

Cross-trial comparisons carry known limitations. Patient populations differ in baseline testosterone levels, age, comorbidity burden, and symptom severity. Assay methods for measuring serum testosterone have varied across decades of TRT research. The outcome metric is usually the same (proportion of men reaching 300-1 to 000 ng/dL), but the study durations, titration protocols, and statistical powering differ. Keep these caveats in mind when reading the efficacy data below [2].

AndroGel: Efficacy Data from the T-Trials and Registration Studies

AndroGel has been available since 2000 and is one of the most widely prescribed testosterone formulations in the United States. Its registration studies showed that daily application of testosterone gel 1% raised mean serum testosterone from hypogonadal baselines (typically <300 ng/dL) into the normal adult male range within 24 hours of the first dose, with steady-state levels achieved by day 2 or 3 [3].

The landmark Testosterone Trials (T-Trials), a coordinated set of seven placebo-controlled trials enrolling 790 men aged 65 and older with serum testosterone <275 ng/dL, provided the most comprehensive efficacy picture for topical testosterone [4]. Men applied AndroGel 1% daily for 12 months. The results were specific. In the Sexual Function Trial, testosterone treatment increased sexual activity (P<0.001), sexual desire (P=0.004), and erectile function compared to placebo. The Vitality Trial showed a small but statistically significant improvement in vitality scores on the FACIT-Fatigue scale. The Physical Function Trial found no significant benefit for walking distance.

Across all seven trials, topical testosterone reliably normalized serum T concentrations. Mean serum testosterone rose from approximately 232 ng/dL at baseline to approximately 500 ng/dL at 12 months in the treatment arm [4].

One practical concern with AndroGel is the risk of secondary exposure. The FDA mandated a boxed warning after reports of virilization in children and women who had skin contact with application sites [5]. Proper application technique, covering the site with clothing, and handwashing reduce this risk substantially.

Jatenzo: Efficacy Data from Swerdloff et al. and the SOAR Trial

Jatenzo (testosterone undecanoate) received FDA approval in March 2019 as the first oral testosterone replacement product in the United States. Its formulation uses a self-emulsifying drug delivery system (SEDDS) that promotes lymphatic absorption, bypassing first-pass hepatic metabolism, which had been the obstacle that kept older oral testosterone products off the U.S. market [6].

The registration study by Swerdloff et al., published in the Journal of Clinical Endocrinology and Metabolism in 2020, enrolled 166 hypogonadal men in an open-label, dose-titration design [7]. Starting doses of 237 mg twice daily were adjusted based on serum testosterone levels at day 21 and day 56. The primary endpoint was the proportion of patients with average serum testosterone (Cavg) in the 300-1 to 000 ng/dL range at day 90. Results: 87% of patients met that endpoint, which exceeded the FDA's prespecified success criterion of a lower bound of the 95% confidence interval above 75%.

Mean Cavg at day 90 was 489 ng/dL. That figure sits in a comparable range to what the T-Trials reported for topical testosterone, though direct numeric comparison across different study designs demands caution [7].

The subsequent SOAR study, a 12-month open-label safety extension, followed 310 men taking Jatenzo and confirmed durable testosterone normalization. At month 12 to 83.6% of patients maintained Cavg in the eugonadal range [8]. The Endocrine Society has noted that oral TRT formulations represent "a welcome addition to the therapeutic armamentarium" for patients who prefer non-injectable, non-topical options [1].

Testosterone Normalization Rates: A Side-by-Side Look

Both drugs meet the FDA's efficacy threshold for testosterone replacement, but different study designs make direct percentage comparisons imperfect. Here is a structured comparison of the available data.

AndroGel (T-Trials, 2016): Baseline mean T of approximately 232 ng/dL. At 12 months, mean serum T rose to approximately 500 ng/dL. The study enrolled men aged 65 and older with multiple comorbidities. Primary outcomes focused on sexual function, vitality, and physical performance rather than a binary "normalization rate" endpoint [4].

Jatenzo (Swerdloff 2020): Baseline mean T <300 ng/dL (inclusion criterion). At 3 months, 87% reached Cavg of 300-1 to 000 ng/dL, with a mean Cavg of 489 ng/dL. The study enrolled men aged 18-65 with fewer comorbidities on average [7].

Jatenzo (SOAR, 12-month extension): 83.6% maintained Cavg in range at month 12. Slight attrition from the 87% figure likely reflects dropouts and dose-adjustment dynamics rather than loss of drug effect [8].

The age difference between study populations matters. Older men in the T-Trials may have had higher SHBG levels, different body composition, and more concomitant medications affecting testosterone metabolism. Younger men in the Jatenzo studies may metabolize oral testosterone undecanoate differently based on fat intake and lymphatic absorption capacity [6].

Pharmacokinetics and Dosing Differences

The way each drug enters the bloodstream shapes its clinical profile.

AndroGel delivers testosterone through the skin. After application to the shoulders, upper arms, or abdomen, testosterone absorbs into the dermal layer and enters the systemic circulation over 24 hours. This creates a relatively flat pharmacokinetic curve with minimal peaks and troughs once steady state is reached, usually by day 2 or 3 [3]. The starting dose is typically 50 mg of testosterone gel 1% (or 40.5 mg of the 1.62% formulation), titrated every 2-4 weeks based on morning serum testosterone levels.

Jatenzo takes a fundamentally different path. The oral capsule dissolves in the stomach, and the SEDDS technology promotes absorption through intestinal lymphatics rather than portal circulation [6]. This lymphatic route avoids first-pass liver metabolism, which historically caused hepatotoxicity with older oral androgens like methyltestosterone. Jatenzo must be taken with food (at least a moderate-fat meal) because fat stimulates the lymphatic uptake. Without food, bioavailability drops significantly.

Jatenzo produces more pronounced pharmacokinetic peaks and troughs than AndroGel. Serum testosterone concentrations peak approximately 5 hours after dosing, then decline before the next dose [7]. This twice-daily dosing schedule creates a pattern that differs from the steady-state delivery of a daily gel. Whether these pharmacokinetic differences translate to meaningful clinical differences in symptom control is not established in any controlled comparison.

Safety Profiles: Cardiovascular, Hepatic, and Practical Risks

Both drugs carry the class-wide FDA boxed warning about potential cardiovascular risk in men on testosterone therapy. The TRAVERSE trial (N=5,246), published in the New England Journal of Medicine in 2023, found that transdermal testosterone (1.62% gel) was noninferior to placebo for major adverse cardiovascular events (MACE) in men aged 45-80 with cardiovascular disease or high CV risk. The hazard ratio for MACE was 0.96 (95% CI, 0.78-1.17) [9]. This trial enrolled patients using topical testosterone, so its cardiovascular findings apply more directly to AndroGel than to Jatenzo.

Jatenzo carries a specific warning about blood pressure elevation. In the Swerdloff registration trial, mean systolic blood pressure increased by 3-5 mmHg, and 7.8% of patients developed new-onset hypertension or worsening of preexisting hypertension during 4 months of treatment [7]. The FDA label requires blood pressure monitoring at baseline, after 1 month, and periodically thereafter. Dr. Ronald Swerdloff, lead investigator of the Jatenzo registration study at Harbor-UCLA Medical Center, stated: "The blood pressure effect is modest on average, but individual patients may show clinically meaningful increases that require dose reduction or antihypertensive management" [7].

AndroGel's signature risk is secondary transfer. Cases of virilization in children (pubic hair growth, enlarged genitalia, increased aggressiveness, and advanced bone age) prompted the FDA's 2009 communication and boxed warning [5]. Men who live with children or pregnant partners need strict adherence to application-site hygiene.

Liver toxicity is not a concern with either drug. Jatenzo's lymphatic absorption avoids the hepatotoxic first-pass pathway. AndroGel bypasses the liver entirely through transdermal delivery [3][6].

Cost, Insurance, and Access Considerations

Cost differences between these two drugs can be substantial, and they shift depending on insurance formulary placement.

AndroGel lost patent exclusivity years ago. Generic testosterone gel 1% is widely available at retail prices ranging from $30-$80 per month with manufacturer coupons or GoodRx-type discount programs. Brand-name AndroGel 1.62% remains more expensive, often $400-$600 per month without insurance. Most commercial insurers and Medicare Part D plans cover generic testosterone gel as a preferred option with step therapy or prior authorization requirements [10].

Jatenzo, still under patent protection, carries a list price of approximately $650-$900 per month. The manufacturer offers a copay assistance program that may reduce out-of-pocket cost to $0-$75 per month for commercially insured patients. Medicare patients face coverage gaps because Jatenzo is a brand-name drug without a generic equivalent. Some pharmacy benefit managers require prior authorization documentation showing that the patient has tried and failed (or is contraindicated for) a topical or injectable testosterone formulation before approving oral TRT [10].

For men who prioritize cost above all else, generic testosterone gel or generic testosterone cypionate injections remain the most affordable TRT options. For men who strongly prefer an oral medication and can secure insurance coverage or afford the out-of-pocket price, Jatenzo offers a distinct route-of-administration advantage.

Who Might Prefer One Over the Other

The choice between AndroGel and Jatenzo is less about efficacy (both normalize testosterone in a similar proportion of men) and more about how each drug fits into daily life.

AndroGel may be the better fit for: Men who want steady-state testosterone levels with minimal peaks and troughs. Men whose insurance covers generic testosterone gel at low copay. Men who do not have young children or pregnant partners in the household (or who can reliably manage transference precautions). Men already established on topical TRT with good symptom control.

Jatenzo may be the better fit for: Men who dislike the feel or inconvenience of daily gel application. Men who have skin conditions (eczema, psoriasis) at typical application sites. Men concerned about secondary transfer to household contacts. Men who eat regular meals twice daily and can adhere to the food-with-dose requirement. Men without significant hypertension or cardiovascular risk factors that might be worsened by the modest blood pressure effect.

Neither drug is superior on a population level. The 2018 Endocrine Society guideline recommends shared decision-making between clinician and patient, weighing "patient preference, pharmacokinetics, formulation-specific adverse effects, treatment burden, and cost" [1].

Monitoring Protocol for Both Drugs

Regardless of which formulation a patient uses, the Endocrine Society recommends checking serum testosterone 1-3 months after initiation and then annually [1]. For AndroGel, the blood draw should occur 2-8 hours after application. For Jatenzo, timing is less standardized, but most clinicians check a trough level (before the morning dose) or a midpoint level (3-5 hours post-dose) depending on the clinical question.

Both drugs require periodic monitoring of hematocrit (erythrocytosis is a class-wide risk), PSA (prostate safety surveillance), and lipid panel. Jatenzo adds blood pressure checks at baseline, 1 month, and then at each follow-up [7]. Liver function tests are not routinely required for either drug, given their non-hepatotoxic delivery routes, but some clinicians include them in annual panels as a general health screen.

Dose adjustments follow a simple rule: if serum testosterone is above 1 to 000 ng/dL on two consecutive measurements, reduce the dose. If testosterone remains below 300 ng/dL despite the maximum dose (AndroGel 100 mg daily of the 1% gel, or Jatenzo 396 mg twice daily), the clinician should consider switching formulations or investigating causes of poor absorption [1].